BRPI0519070A2 - composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa - Google Patents

composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa

Info

Publication number
BRPI0519070A2
BRPI0519070A2 BRPI0519070-3A BRPI0519070A BRPI0519070A2 BR PI0519070 A2 BRPI0519070 A2 BR PI0519070A2 BR PI0519070 A BRPI0519070 A BR PI0519070A BR PI0519070 A2 BRPI0519070 A2 BR PI0519070A2
Authority
BR
Brazil
Prior art keywords
growth factor
preparing
keratinocyte growth
lyophilized
composition
Prior art date
Application number
BRPI0519070-3A
Other languages
English (en)
Inventor
Michael J Treuheit
Vasumathi Dharmavaram
Judith Purtell
Suzanne E Roy
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0519070A2 publication Critical patent/BRPI0519070A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIÇçO DE FATOR DE CRESCIMENTO DE QUERATINàCITO LIOFILIZADA, MÉTODOS PARA PREPARAR UM FATOR DE CRESCIMENTO DE QUERATINàCITO LIOFILIZADO, E PARA TRATAR UMA DOENÇA, E, KIT PARA PREPARAR UMA COMPOSIÇçO FARMACÊUTICA AQUOSA. A presente invenção proporciona formulações estáveis de longa duração de fator de crescimento de queratinócito liofihizado e métodos para preparar uma composição liofihizada compreendendo fator de crescimento de queratinócito.
BRPI0519070-3A 2004-12-15 2005-12-12 composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa BRPI0519070A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63621004P 2004-12-15 2004-12-15
PCT/US2005/045169 WO2006065861A2 (en) 2004-12-15 2005-12-12 Therapeutic formulations of keratinocyte growth factor

Publications (1)

Publication Number Publication Date
BRPI0519070A2 true BRPI0519070A2 (pt) 2008-12-23

Family

ID=36337531

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519070-3A BRPI0519070A2 (pt) 2004-12-15 2005-12-12 composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa

Country Status (27)

Country Link
US (1) US8304387B2 (pt)
EP (1) EP1827483B1 (pt)
JP (1) JP5201992B2 (pt)
KR (1) KR101283736B1 (pt)
CN (1) CN101084008B (pt)
AR (1) AR052339A1 (pt)
AU (1) AU2005317166B2 (pt)
BR (1) BRPI0519070A2 (pt)
CA (1) CA2589889C (pt)
CR (1) CR9246A (pt)
DK (1) DK1827483T3 (pt)
EA (1) EA013369B1 (pt)
ES (1) ES2504441T3 (pt)
HR (1) HRP20140926T1 (pt)
IL (1) IL183435A (pt)
MX (1) MX2007006822A (pt)
MY (1) MY145638A (pt)
NO (1) NO20073629L (pt)
NZ (1) NZ555503A (pt)
PL (1) PL1827483T3 (pt)
PT (1) PT1827483E (pt)
RS (1) RS53548B1 (pt)
SI (1) SI1827483T1 (pt)
TW (1) TWI351966B (pt)
UA (1) UA88497C2 (pt)
WO (1) WO2006065861A2 (pt)
ZA (1) ZA200706095B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005317166B2 (en) 2004-12-15 2009-09-10 Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
US20090186805A1 (en) * 2006-07-06 2009-07-23 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
CN101780269A (zh) * 2009-01-21 2010-07-21 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
IT1396020B1 (it) * 2009-10-16 2012-11-09 Fitologica Srl Composizione topica a base di biopeptidi, e suo utilizzo in campo tricologico.
CN102675449B (zh) * 2011-03-17 2016-06-08 重庆富进生物医药有限公司 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途
CN102379838B (zh) * 2011-11-02 2013-06-12 广州舒泰生物技术有限公司 一种舒缓静颜化妆品的制备方法及应用
EP2773364A1 (en) * 2011-11-02 2014-09-10 The University of Chicago Stable pharmaceutical formulations of growth factor peptides
US20150126433A1 (en) * 2012-04-25 2015-05-07 University Of Cincinnati Growth factors for the treatment of mycobacterial infection
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
CN108359634A (zh) * 2018-02-02 2018-08-03 江阴司特易生物技术有限公司 一种饲养细胞蛋白复合物及其应用
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
CN114040781A (zh) * 2019-06-24 2022-02-11 杭州多禧生物科技有限公司 Tubulysin衍生物与细胞结合分子偶联物的制剂配方
CN110339345B (zh) * 2019-07-30 2022-11-29 重庆派金生物科技有限公司 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof
CN119632934A (zh) * 2025-02-19 2025-03-18 杭州熙岭生物科技有限公司 一种kgf-2组合物的冻干粉及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2250213C2 (ru) * 1989-01-31 2005-04-20 Джеффри С. РУБИН Выделенный белок фактора роста кератиноцита (kgf), рекомбинантная молекула днк, вектор, способ конструирования клетки-хозяина, способ получения белка, фармацевтическая композиция
US7026291B1 (en) * 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
DE69232847T2 (de) * 1991-12-20 2003-09-11 Novo Nordisk A/S, Bagsvaerd Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
CA2166278A1 (en) * 1993-06-29 1995-01-12 Denis J. Gospodarowicz A truncated keratinocyte growth factor (kgf) having increased biological activity
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
SI0785950T1 (en) 1994-10-13 2003-08-31 Amgen Inc. Keratinocyte growth factor analogs
WO1996011949A2 (en) 1994-10-13 1996-04-25 Amgen Inc. Analogs of keratinocyte growth factor
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
EP1012186B1 (en) * 1996-12-06 2002-07-17 Amgen Inc., Use of a kgf protein product(s) and a glp-2 protein product(s) for the preparation of a medicament
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CN1359299A (zh) * 1999-06-02 2002-07-17 人类基因组科学公司 角质细胞生长因子－2制剂
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
AU2005317166B2 (en) 2004-12-15 2009-09-10 Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor

Also Published As

Publication number Publication date
MX2007006822A (es) 2007-07-24
EA200701293A1 (ru) 2008-02-28
TW200635603A (en) 2006-10-16
NZ555503A (en) 2010-01-29
KR20070093977A (ko) 2007-09-19
EP1827483B1 (en) 2014-07-02
ZA200706095B (en) 2008-09-25
EP1827483A2 (en) 2007-09-05
WO2006065861A3 (en) 2006-08-17
EA013369B1 (ru) 2010-04-30
CN101084008A (zh) 2007-12-05
CA2589889C (en) 2013-07-30
CA2589889A1 (en) 2006-06-22
HRP20140926T1 (hr) 2014-11-07
AU2005317166B2 (en) 2009-09-10
MY145638A (en) 2012-03-15
HK1115298A1 (en) 2008-11-28
DK1827483T3 (da) 2014-10-06
US8304387B2 (en) 2012-11-06
RS53548B1 (sr) 2015-02-27
KR101283736B1 (ko) 2013-07-08
JP5201992B2 (ja) 2013-06-05
TWI351966B (en) 2011-11-11
JP2008524229A (ja) 2008-07-10
UA88497C2 (ru) 2009-10-26
AU2005317166A1 (en) 2006-06-22
WO2006065861A2 (en) 2006-06-22
CR9246A (es) 2007-10-23
IL183435A0 (en) 2007-09-20
US20060128622A1 (en) 2006-06-15
AR052339A1 (es) 2007-03-14
NO20073629L (no) 2007-09-10
PT1827483E (pt) 2014-09-25
PL1827483T3 (pl) 2014-12-31
IL183435A (en) 2010-11-30
SI1827483T1 (sl) 2014-11-28
ES2504441T3 (es) 2014-10-08
CN101084008B (zh) 2013-04-10

Similar Documents

Publication Publication Date Title
BRPI0710508B8 (pt) composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído
BRPI0519070A2 (pt) composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
CR20230149A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas (divisional exp no 2022-539)
BRPI0512347A (pt) preparação da pregabalina e compostos relacionados
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
CY1116700T1 (el) Παρασκευη συνθετικου χολικου οξεος
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
BRPI0407181A (pt) Formulação farmacêutica
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
BRPI0818267A2 (pt) Novos derivados de 1,3-dihidro-5-isobenzofuranocarbonitrila e composição farmacêutica dos mesmos para o tratamento de ejaculação precoce
BRPI0519312A2 (pt) composiÇço biologicamente ativa, composiÇço de liofilizaÇço, mÉtodo para a liofilizaÇço de virossomas utilizando as composiÇÕes, liofilizado de virossoma, mÉtodo para reconstituiÇço de um liofilizado de virossoma, uso de qualquer uma das composiÇÕes, kit, e, uso de um derivado de colesterila catiânico
DE602004019528D1 (de) Usammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIOVITRUM AB (PUBL) (SE)

Free format text: TRANSFERIDO DE: AMGEN INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]